$DRTS
Alpha Tau Medical Ltd. Stock $drts

$drts Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023018883 Filed on March 09, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.605M	$11.25M	$2.343M
YoY Change	11.18%	379.98%	37.82%
% of Gross Profit
Research & Development	$5.380M	$20.89M	$11.45M
YoY Change	-53.0%	82.49%	51.74%
% of Gross Profit
Depreciation & Amortization	$504.0K	$979.0K	$776.0K
YoY Change	-35.05%	26.16%	802.33%
% of Gross Profit
Operating Expenses	$7.985M	$32.14M	$13.79M
YoY Change	-42.1%	133.04%	2757900.0%
Operating Profit		-$32.14M
YoY Change		133.04%
Interest Expense	$4.592M	$2.203M	-$201.0K
YoY Change	-2384.58%	-1196.02%	-128.15%
% of Operating Profit
Other Income/Expense, Net		$16.55K	-$13.27M
YoY Change		-100.12%	6741.75%
Pretax Income	-$3.393M	-$33.74M	-$27.26M
YoY Change	-87.56%	23.76%	5452700.0%
Income Tax	$3.000K	$20.00K	$7.000K
% Of Pretax Income
Net Earnings	-$3.396M	-$33.76M	-$27.27M
YoY Change	-87.55%	23.8%	5454100.0%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.53
Diluted Earnings Per Share	-$0.05	-$0.53	-$398.2K
COMMON SHARES
Basic Shares Outstanding	69.11M shares	63.53M shares
Diluted Shares Outstanding		63.53M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$104.5M	$104.5M	$31.32M
YoY Change	233.79%	233.79%
Cash & Equivalents	$5.836M	$5.836M	$23.24M
Short-Term Investments	$98.69M	$98.69M	$8.080M
Other Short-Term Assets	$1.947M	$1.915M	$1.325M
YoY Change	46.94%	46.97%	702.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$106.5M	$106.5M	$32.64M
YoY Change	226.21%	226.21%	19678.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.471M	$13.28M	$7.546M
YoY Change	-0.99%	76.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$391.0K	$391.0K	$2.028M
YoY Change	-80.72%	-80.72%
Total Long-Term Assets	$13.67M	$13.67M	$9.574M
YoY Change	42.8%	42.8%
TOTAL ASSETS
Total Short-Term Assets	$106.5M	$106.5M	$32.64M
Total Long-Term Assets	$13.67M	$13.67M	$9.574M
Total Assets	$120.1M	$120.1M	$42.22M
YoY Change	184.61%	184.61%	25480.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.423M	$1.423M	$1.203M
YoY Change	18.29%	13.75%
Accrued Expenses	$1.276M	$2.852M	$2.366M
YoY Change	-46.07%	-9.58%	4489.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.338M	$4.338M	$4.405M
YoY Change	-1.52%	-1.52%	3015.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.15M	$10.15M	$18.62M
YoY Change	-45.48%	-45.48%
Total Long-Term Liabilities	$10.15M	$10.15M	$18.62M
YoY Change	-45.48%	-45.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.338M	$4.338M	$4.405M
Total Long-Term Liabilities	$10.15M	$10.15M	$18.62M
Total Liabilities	$14.49M	$14.49M	$23.03M
YoY Change	-37.07%	-37.07%	16185.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$86.60M		-$52.84M
YoY Change	63.89%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$105.7M	$105.7M	$19.19M
YoY Change
Total Liabilities & Shareholders Equity	$120.1M	$120.1M	$42.22M
YoY Change	184.61%	184.61%	25480.2%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.396M	-$33.76M	-$27.27M
YoY Change	-87.55%	23.8%	5454100.0%
Depreciation, Depletion And Amortization	$504.0K	$979.0K	$776.0K
YoY Change	-35.05%	26.16%	802.33%
Cash From Operating Activities	-$8.551M	-$23.88M	-$10.95M
YoY Change	-21.92%	102.16%
INVESTING ACTIVITIES
Capital Expenditures	$229.0K	$904.0K	-$2.927M
YoY Change	-107.82%	-130.88%	-22.3%
Acquisitions
YoY Change
Other Investing Activities	$2.968M	-$89.03M	$297.2M
YoY Change	-99.0%	-501.05%	-7438.27%
Cash From Investing Activities	$2.739M	-$89.94M	$294.3M
YoY Change	-99.07%	-566.64%	-3864.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$276.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	105.0K	$96.91M	-276.5M
YoY Change	-100.04%	87201.8%
NET CHANGE
Cash From Operating Activities	-8.551M	-$23.88M	-10.95M
Cash From Investing Activities	2.739M	-$89.94M	294.3M
Cash From Financing Activities	105.0K	$96.91M	-276.5M
Net Change In Cash	-5.707M	-$17.17M	6.839M
YoY Change	-183.45%	-326.73%
FREE CASH FLOW
Cash From Operating Activities	-$8.551M	-$23.88M	-$10.95M
Capital Expenditures	$229.0K	$904.0K	-$2.927M
Free Cash Flow	-$8.780M	-$24.78M	-$8.024M
YoY Change	9.42%	178.93%	-313.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41316
CY2022	dei	Entity Registrant Name EntityRegistrantName	Alpha Tau Medical Ltd.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	Kiryat HaMada St. 5
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Jerusalem
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	9777605
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Security12b Title Security12bTitle	Ordinary shares, no par value
CY2022	dei	Trading Symbol TradingSymbol	DRTS
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69105000	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1281
CY2022	dei	Auditor Name AuditorName	KOST FORER GABBAY & KASIERER
CY2022	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23236000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5836000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	618000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	850000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	8080000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	98694000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	707000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1097000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	32641000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	106477000	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	2028000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	391000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7546000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7471000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5810000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	9574000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	13672000	usd
CY2021Q4	us-gaap	Assets Assets	42215000	usd
CY2022Q4	us-gaap	Assets Assets	120149000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1203000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1423000	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3202000	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2246000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	669000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4405000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4338000	usd
CY2022Q4	drts	Warrantliability Warrantliability	5630000	usd
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	18623000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4524000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	23028000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14492000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	25348176	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	13739186	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	13739186	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	53964000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	72423360	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	362116800	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40528913	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40528913	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69105000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69105000	shares
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18063000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192259000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52840000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86602000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-34777000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	105657000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42215000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	120149000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7544000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11447000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20890000	usd
CY2020	us-gaap	Marketing Expense MarketingExpense	288000	usd
CY2021	us-gaap	Marketing Expense MarketingExpense	482000	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	974000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1412000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1861000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10272000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-9244000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13790000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-32136000	usd
CY2020	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	520000	usd
CY2021	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-13474000	usd
CY2022	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-1606000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8724000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27264000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33742000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	158000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-8882000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8882000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27271000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33762000	usd
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63534875	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-193000	usd
CY2020	drts	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	30000	usd
CY2020	drts	Stock Issued During Period Value Ordinary Shares Upon Exercise Of Share Options StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions	20000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	596000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-8882000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-8429000	usd
CY2021	drts	Stock Issued During Period Value Ordinary Shares Upon Exercise Of Share Options StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions	111000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	812000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-34777000	usd
CY2022	drts	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	3335000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	74952000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	53964000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	35170000	usd
CY2022	drts	Stock Issued During Period Value Ordinary Shares Upon Exercise Of Share Options StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions	27000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6748000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	105657000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-8882000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-27271000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33762000	usd
CY2020	us-gaap	Depreciation Depreciation	86000	usd
CY2021	us-gaap	Depreciation Depreciation	776000	usd
CY2022	us-gaap	Depreciation Depreciation	979000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	596000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	812000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	6748000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-283000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-157000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	341000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	123000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1889000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1637000	usd
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	203000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	13257000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3788000	usd
CY2020	drts	Increase Decrease In Non Cash Financial Income Expenses IncreaseDecreaseInNonCashFinancialIncomeExpenses	153000	usd
CY2021	drts	Increase Decrease In Non Cash Financial Income Expenses IncreaseDecreaseInNonCashFinancialIncomeExpenses	-29000	usd
CY2022	drts	Increase Decrease In Non Cash Financial Income Expenses IncreaseDecreaseInNonCashFinancialIncomeExpenses	1325000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	114000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	239000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	220000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	625000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2078000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1206000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1152000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-535000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7251000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11812000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23879000	usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	70200000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	8082000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	121137000	usd
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	66150000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	30282000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	32105000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3767000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2927000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	904000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7817000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19273000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89936000	usd
CY2022	drts	Proceeds From Spac Merger And Pipe Financing Net Of Transaction Cost ProceedsFromSPACMergerAndPIPEFinancingNetOfTransactionCost	93543000	usd
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	28726000	usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	571000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3335000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	111000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29317000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96905000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-258000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14333000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7680000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17168000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1841000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16174000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23854000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16174000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23854000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6686000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	541000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	351000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	237000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"/><td style="width: 0.75in; text-align: left">NOTE 1: -</td><td style="text-align: justify">GENERAL</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"/> <td style="width: 0.5in">a.</td> <td style="text-align: justify">Company description:</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">Alpha Tau Medical Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November 2015 and began its operations in January 2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera Medical Ltd., (“Althera”), developed in 2003 at Tel Aviv University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">In August 2017 the Company established a fully owned subsidiary in the United States - “Alpha Tau Medical Inc.” (“ATM Inc.”). ATM Inc. began its activity in August 2018.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">In January 2018 the Company established a subsidiary in Japan “Alpha Tau Medical KK” (hereafter: ATM KK). ATM KK began its activity in January 2018. Since July 2019, the Company holds 100% of ATM KK.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">In July 2019, the Company established a fully owned subsidiary in Canada “Alpha Tau Medical Canada Inc.” (“ATM Canada Inc.”). ATM Canada Inc. began its activity in March 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.75in"/> <td style="text-align: justify; width: 0.5in">b.</td> <td style="text-align: justify">Merger with Healthcare Capital Corp:</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">On July 7, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Healthcare Capital Corp., a Delaware corporation (“HCCC”), and Archery Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”). As part of the completion of business combination on March 7, 2022 (the “Closing Date”), the Merger Sub was merged with and into HCCC (the “Merger”), with HCCC surviving the merger as a wholly owned subsidiary of the Company. In July 2022, HCCC was dissolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">Each of HCCC’s outstanding warrants to purchase one share of HCCC common stock, including both the HCCC warrants issued to public shareholders in HCCC’s initial public offering (the “Public Warrants”) and the HCCC warrants issued in a private placement to HCCC’s sponsors in HCCC’s initial public offering (the “Private Warrants”) (together, the “Warrants liability”), were converted into the right to receive an equal number of warrants to purchase one Ordinary Share of the Company. A total of 15,891,984 warrants to purchase one Ordinary Share were issued to holders of HCCC warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">On July 7, 2021, the Company entered into Subscription Agreements, together with a number of subsequent agreements since with certain investors (the “PIPE Investors”) pursuant to which, among other things, the PIPE Investors agreed to purchase on the Closing Date the Company’s ordinary shares at a price equal to $10.00 per share on the terms and subject to the conditions set forth in the Subscription Agreements (the “PIPE Financing”). In connection with the closing of the Business Combination, the Company consummated the sale of 9,251,006 ordinary shares for gross proceeds of $92,510 pursuant to the PIPE Financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">Total gross proceeds resulted from the Merger transaction were approximately $104,052 out of which total transaction costs amounted to approximately $5,713. The transaction costs related to the Warrants liability in the amount of $817 were recognized as expenses in the Company’s consolidated statements of operations. The residual amount was recognized as additional paid in capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">On July 6, 2021, the Company’s board of directors approved a 1: 0.905292 stock split which was effected on March 7, 2022. As a result, all Ordinary shares, Convertible Preferred shares, options for Ordinary Shares, warrants to Ordinary shares and Preferred shares, exercise price and net loss per share amounts were adjusted accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.75in"/> <td style="text-align: justify; width: 0.5in">c.</td> <td style="text-align: justify">The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to secure financing; obtain further marketing approvals from regulatory authorities; access potential markets; and build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">As of December 31, 2022, the Company had cash, cash equivalents, short-term deposits and restricted cash of $105,380. During the year ended December 31, 2022, the Company incurred a net loss of $33,762 and had negative cash flows from operating activities of $23,879. In addition, the Company had an accumulated deficit of $86,602 on December 31, 2022. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least two years.</p>
CY2018Q1	drts	Ownership Percentage OwnershipPercentage	1	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	15891984	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	9251006	shares
CY2021Q3	drts	Gross Proceeds GrossProceeds	92510000	usd
CY2022	drts	Gross Proceeds GrossProceeds	104052000	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	5713000	usd
CY2021Q3	drts	Stock Split Description StockSplitDescription	the Company’s board of directors approved a 1: 0.905292 stock split which was effected on March 7, 2022
CY2022	drts	Cash Cash Equivalents Short Term Deposits And Restricted Cash CashCashEquivalentsShortTermDepositsAndRestrictedCash	105380000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	33762000	usd
CY2022	drts	Negative Cash Flows From Operating Activities NegativeCashFlowsFromOperatingActivities	23879000	usd
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	86602000	usd
CY2022	drts	Liquidity Requirements LiquidityRequirements	P2Y
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.75in"/> <td style="text-align: justify; width: 0.5in">a.</td> <td style="text-align: justify">Use of estimates for the preparation of financial statements:</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair values of warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"> </p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23236000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5836000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	618000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	850000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	23854000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	6686000	usd
CY2020	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	878000	usd
CY2021	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	2459000	usd
CY2022	us-gaap	Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred	1343000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	596000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	812000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6748000	usd
CY2021Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	912000	usd
CY2022Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	1891000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	7546000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	7471000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.50	pure
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"/> <td style="width: 0.5in">p.</td> <td style="text-align: justify">Concentration of credit risks:</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0pt">Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"> </p>
CY2022	drts	Severance Pay Deposit Rate SeverancePayDepositRate	8.33%
CY2020	drts	Severance Pay Expense SeverancePayExpense	194000	usd
CY2021	drts	Severance Pay Expense SeverancePayExpense	318000	usd
CY2022	drts	Severance Pay Expense SeverancePayExpense	418000	usd
CY2022Q1	drts	Assets And Lease Liabilities AssetsAndLeaseLiabilities	6089000	usd
CY2021Q4	drts	Government Authorities Receivable GovernmentAuthoritiesReceivable	458000	usd
CY2022Q4	drts	Government Authorities Receivable GovernmentAuthoritiesReceivable	281000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	227000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	784000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	22000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	32000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	707000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1097000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8458000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9362000	usd
CY2020	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	86000	usd
CY2021	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	776000	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	979000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	775000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	18000	usd
CY2022	us-gaap	Lease Cost LeaseCost	793000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	688000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	613000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	568000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	571000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4533000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6973000	usd
CY2022Q4	us-gaap	Interest Portion Of Minimum Lease Payments Sale Leaseback Transactions InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions	1780000	usd
CY2022Q4	us-gaap	Present Value Of Future Minimum Lease Payments Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions	5193000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	788000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	907000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2366000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1276000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	63000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3202000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2246000	usd
CY2022Q4	drts	Short Term Bank Loans And Note Payable ShortTermBankLoansAndNotePayable	850	usd
CY2022	drts	Aggregate Amount aggregateAmount	5155	usd
CY2022	drts	Royalty Rate RoyaltyRate	0.07	pure
CY2022	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	In whole and not in part; ●At a price of $0.01 per warrant; ● Upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and ● If, and only if, the closing price of the Ordinary shares equals or exceeds $18.00 per share (subject to standard adjustments) for any 20 trading days within a 30-trading day period ending three business days before the Company sends to the notice of redemption to the warrant holders.
CY2021Q4	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	25384176	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	13739186	shares
CY2022Q1	drts	Stockholders Equity Note Stock Split Conversion Ratio StockholdersEquityNoteStockSplitConversionRatio	1: 0.905292
CY2022Q4	drts	Convertible Preferred Shares Outstanding ConvertiblePreferredSharesOutstanding	13739186	shares
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	14270797	shares
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.67
CY2022	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	53964	usd
CY2021	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.50	pure
CY2022	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	3880777	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.87
CY2022Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	3880777	shares
CY2022	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	3.87
CY2022	us-gaap	Other Expenses OtherExpenses	16547	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2323960	shares
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.905292	pure
CY2021Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	72423360	shares
CY2021Q4	us-gaap	Common Unit Issued CommonUnitIssued	40528913000	shares
CY2022Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	362116800	shares
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	69105000000	shares
CY2021Q3	drts	Shares Number Of Votes SharesNumberOfVotes	1	pure
CY2020Q4	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	372000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	654000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4289000	usd
CY2020Q4	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	20000	usd
CY2021	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	7000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	210000	usd
CY2020Q4	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	204000	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	151000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	2249000	usd
CY2020Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	596000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	812000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	6748000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	16301000	usd
CY2019Q3	drts	Weighted Average Period WeightedAveragePeriod	P3Y10D
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	4420	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	9810	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	8080.00	usd
CY2020	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	760	usd
CY2021	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	4450	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3760	usd
CY2022	drts	Warrants Issued To Investors Description WarrantsIssuedToInvestorsDescription	(i)As part of 2016 investment round, the Company granted the investors 6,789,694 Warrants. In December 2019, these Warrants were exercised into 5,316,493 Ordinary shares of no-par value, of them 1,412,520 were exercised on a cash basis in consideration of approximately $1,560, and 5,377,174 were exercised on a cashless basis at a ratio of approximately 0.73 Ordinary share per exercised Warrant. (ii) As part of the 2018 SPA, the Company granted 9,053 Warrants to Ordinary shares to a public service foundation in Israel. The Warrants were exercised on July 15, 2021 into 9,053 Ordinary shares of no-par value with no consideration. (iii) In July 2019, as part of the investment round of HekaBio K.K, the investors received 651,067 Warrants to Ordinary shares with an exercise price of $5.04 to be exercise within 4 years from grant date. During the year ended December 31, 2022, all 651,067 Warrants were exercised into 308,540 ordinary shares of the Company. (iv) In April 2020, 879,609 Warrants were exercised into 556,548 Ordinary shares of no-par value, for $30 received in cash and the rest exercised on a cashless basis. (v) Upon completion of the Merger, the 3,880,777 warrants convertible into Preferred A Shares of the Company were converted into an identical number of warrants convertible into ordinary shares of the Company until September 2024 at an exercise price of $3.87 (see also notes 2 n and 10).
CY2022	drts	Number Of Warrants Exercised NumberOfWarrantsExercised	1556817	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2323960	shares
CY2016Q2	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	67897	shares
CY2016Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P7Y
CY2020Q4	drts	Number Of Warrants Exercised NumberOfWarrantsExercised	90529	shares
CY2020Q4	drts	Sale Of Stock Number Of Warrants Issued In Transaction SaleOfStockNumberOfWarrantsIssuedInTransaction	67897	shares
CY2022	drts	Reduced Tax Rates ReducedTaxRates	0.075	pure
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	9322000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	27089000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	33100000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-598000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	175000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	642000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8724000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27264000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33742000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	158000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	20000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	158000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	20000	usd
CY2020	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	158000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	20000	usd
CY2022	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	51256000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	18000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	22000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	399000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1018000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	31000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	50000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	94000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	473000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3322000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3950000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3803000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5607000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3803000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5084000	usd
CY2022Q4	drts	Deferred Tax Assets Tax Deferred Expense Rou Asset DeferredTaxAssetsTaxDeferredExpenseROUAsset	523000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.22
CY2021	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	412000	usd
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	203000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	13257000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3788000	usd
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	14000	usd
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	16000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	21000	usd
CY2020	drts	Total Financial Expenses TotalFinancialExpenses	217000	usd
CY2021	drts	Total Financial Expenses TotalFinancialExpenses	13685000	usd
CY2022	drts	Total Financial Expenses TotalFinancialExpenses	3809000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	101000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	413000	usd
CY2020	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	613000	usd
CY2021	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	211000	usd
CY2022	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	1790000	usd
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	23000	usd
CY2020	drts	Financial Income Total FinancialIncomeTotal	737000	usd
CY2021	drts	Financial Income Total FinancialIncomeTotal	211000	usd
CY2022	drts	Financial Income Total FinancialIncomeTotal	2203000	usd
CY2020	drts	Financial Expensesincome Net FinancialExpensesincomeNet	520000	usd
CY2021	drts	Financial Expensesincome Net FinancialExpensesincomeNet	-13474000	usd
CY2022	drts	Financial Expensesincome Net FinancialExpensesincomeNet	-1606000	usd
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8882000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-27271000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-33762000	usd
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	40274935	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	63534875	shares
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.22
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.67
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.53
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22995444	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25349049	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27234182	shares
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	7546000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	13281000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	113000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	265000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	drts	Warrantliability Warrantliability		usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare
CY2021Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40274935	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63534875	shares
CY2020	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues		usd
CY2021	drts	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants		usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2020	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet		usd
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2020	drts	Current Israel Expense Benefits CurrentIsraelExpenseBenefits		usd
CY2021	drts	Current Israel Expense Benefits CurrentIsraelExpenseBenefits		usd
CY2022	drts	Current Israel Expense Benefits CurrentIsraelExpenseBenefits		usd
CY2020	drts	Domestic Israel Tax Expense Benefit DomesticIsraelTaxExpenseBenefit		usd
CY2021	drts	Domestic Israel Tax Expense Benefit DomesticIsraelTaxExpenseBenefit		usd
CY2022	drts	Domestic Israel Tax Expense Benefit DomesticIsraelTaxExpenseBenefit		usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2020	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax		usd
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax		usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40274935	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40534697	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63534875	shares
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.53
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001871321

Files In Submission

Name	View Source	Status
0001213900-23-018883-index-headers.html	Edgar Link	pending
0001213900-23-018883-index.html	Edgar Link	pending
0001213900-23-018883.txt	Edgar Link	pending
0001213900-23-018883-xbrl.zip	Edgar Link	pending
drts-20221231.xsd	Edgar Link	pending
f20f2022ex1-1_alphataumed.htm	Edgar Link	pending
f20f2022ex12-1_alphataumed.htm	Edgar Link	pending
f20f2022ex12-2_alphataumed.htm	Edgar Link	pending
f20f2022ex13-1_alphataumed.htm	Edgar Link	pending
f20f2022ex13-2_alphataumed.htm	Edgar Link	pending
f20f2022ex15-1_alphataumed.htm	Edgar Link	pending
f20f2022ex2-1_alphataumed.htm	Edgar Link	pending
f20f2022ex8-1_alphataumed.htm	Edgar Link	pending
f20f2022_alphataumed.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
drts-20221231_cal.xml	Edgar Link	unprocessable
drts-20221231_def.xml	Edgar Link	unprocessable
drts-20221231_lab.xml	Edgar Link	unprocessable
drts-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f20f2022_alphataumed_htm.xml	Edgar Link	completed
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
image_028.jpg	Edgar Link	pending
image_029.jpg	Edgar Link	pending
image_030.jpg	Edgar Link	pending
image_031.jpg	Edgar Link	pending
image_032.jpg	Edgar Link	pending
image_033.jpg	Edgar Link	pending
image_034.jpg	Edgar Link	pending
image_035.jpg	Edgar Link	pending
image_036.jpg	Edgar Link	pending
image_037.jpg	Edgar Link	pending
image_038.jpg	Edgar Link	pending
image_039.jpg	Edgar Link	pending
image_040.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRTS
Alpha Tau Medical Ltd. Stock $drts

2022 Q4 Form 20-F Financial Statement

#000121390023018883 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRTS Alpha Tau Medical Ltd. Stock $drts

2022 Q4 Form 20-F Financial Statement

#000121390023018883 Filed on March 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRTS
Alpha Tau Medical Ltd. Stock $drts